DeepMed Research

Cogent Biosciences

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2014-01-01

Employees: 164

Market Cap: $1B

Website: http://www.cogentbio.com

Introduction: Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Clinical Trials

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

First Posted Date: 2025-04-29

Last Posted Date: 2025-05-04

Lead Sponsor: Cogent Biosciences, Inc.

Registration Number: NCT06948955

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Conditions: Systemic Mastocytoses, Indolent
Systemic Mastocytoses, Aggressive

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Cogent Biosciences, Inc.

Registration Number: NCT06915766

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Cholangiocarcinoma
Other Solid Tumors, Adult
FGFR2 Gene Fusion/Rearrangement
FGFR2 Gene Amplification
FGFR2 Gene Short Variants
FGFR3 Gene Fusion/Rearrangement
FGFR3 Gene Amplification
FGFR3 Gene Short Variants
FGFR2 Genetic Alterations

Interventions: Drug: CGT4859

First Posted Date: 2025-01-15

Last Posted Date: 2025-05-04

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 110

Registration Number: NCT06777316

Locations: 🇺🇸
Fox Chase cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

and more 7 locations

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Phase 3

Active, not recruiting

Conditions: Advanced Gastrointestinal Stromal Tumors
Metastatic Cancer

Interventions: Drug: CGT9486 plus sunitinib
Drug: Sunitinib
Drug: CGT9486
Drug: Midazolam

First Posted Date: 2022-01-26

Last Posted Date: 2025-05-09

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 442

Registration Number: NCT05208047

Locations: 🇬🇧
Royal Marsden Hospital - Surrey, London, United Kingdom
🇧🇷
lnstituto Nacional de Cancer - INCA, Rio De Janeiro, Brazil
🇨🇱
Centro de Oncologia de Precision, Universidad Mayor, Santiago, Chile

and more 122 locations

(Summit) a Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients with Indolent or Smoldering Systemic Mastocytosis

Phase 2

Active, not recruiting

Conditions: SSM
Mastocytosis, Indolent
Mastocytosis, Systemic
Mastocytosis
ISM
BMM
Smoldering Systemic Mastocytosis
Bone Marrow Mastocytosis

Interventions: Drug: Bezuclastinib Tablets (Formulation B)
Drug: Bezuclastinib Tablets (Formulation A)
Drug: Placebo Tablets

First Posted Date: 2022-01-11

Last Posted Date: 2025-01-10

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 207

Registration Number: NCT05186753

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
One of a Kind Clinical Research Center, Scottsdale, Arizona, United States

and more 66 locations

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Phase 2

Recruiting

Conditions: Advanced Systemic Mastocytosis (AdvSM)
SM With an Associated Hematologic Neoplasm (SM-AHN)
Mast Cell Leukemia (MCL)
Aggressive Systemic Mastocytosis (ASM)

Interventions: Drug: bezuclastinib

First Posted Date: 2021-08-09

Last Posted Date: 2025-03-12

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 140

Registration Number: NCT04996875

Locations: 🇺🇸
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 39 locations

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Phase 1

Terminated

Conditions: HER-2 Protein Overexpression
Solid Tumor

Interventions: Biological: ACTR T Cell Product
Drug: Trastuzumab

First Posted Date: 2018-09-21

Last Posted Date: 2020-03-31

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 6

Registration Number: NCT03680560

Locations: 🇺🇸
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Yale Smilow Cancer Hospital, New Haven, Connecticut, United States

and more 3 locations

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions: Biological: ACTR087
Biological: SEA-BCMA

First Posted Date: 2017-08-30

Last Posted Date: 2020-03-30

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 15

Registration Number: NCT03266692

Locations: 🇺🇸
Baylor Scott & White, Dallas, Texas, United States
🇺🇸
Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 3 locations

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: ACTR707
Biological: rituximab

First Posted Date: 2017-06-16

Last Posted Date: 2021-10-11

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 26

Registration Number: NCT03189836

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Loyola University, Maywood, Illinois, United States

and more 8 locations

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Terminated

Conditions: Solid Tumor
B Cell Lymphomas
HER-2 Protein Overexpression
Multiple Myeloma

Interventions: Other: ACTR T Cell Product

First Posted Date: 2016-07-21

Last Posted Date: 2021-10-11

Lead Sponsor: Cogent Biosciences, Inc.

Target Recruit Count: 22

Registration Number: NCT02840110

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy